Literature DB >> 28660482

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database.

J Remon1, D Isla2, P Garrido3, J de Castro4, M Majem5, N Viñolas6, A Artal7, E Carcereny8, M R García-Campelo9, P Lianes10, M Provencio11, O Juan12, P Diz13, R Blanco14, R Lopez-Castro15, I Maestu16, C Vadell17, E Felip18.   

Abstract

BACKGROUND: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.
METHODS: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.
RESULTS: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.
CONCLUSION: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

Entities:  

Keywords:  Advanced; EGFR mutant; NSCLC; TKI; Women

Mesh:

Substances:

Year:  2017        PMID: 28660482     DOI: 10.1007/s12094-017-1700-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  21 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

Authors:  Eisaku Miyauchi; Akira Inoue; Kunihiko Kobayashi; Makoto Maemondo; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Yasuo Saijo; Hirohisa Yoshizawa; Koichi Hagiwara; Toshihiro Nukiwa
Journal:  Jpn J Clin Oncol       Date:  2015-04-15       Impact factor: 3.019

3.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

4.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

Review 5.  Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.

Authors:  Noemi Reguart; Jordi Remon
Journal:  Future Oncol       Date:  2015-01-28       Impact factor: 3.404

6.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

Review 7.  Risk factors for lung cancer worldwide.

Authors:  Jyoti Malhotra; Matteo Malvezzi; Eva Negri; Carlo La Vecchia; Paolo Boffetta
Journal:  Eur Respir J       Date:  2016-05-12       Impact factor: 16.671

8.  Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07.

Authors:  Dolores Isla; Enriqueta Felip; Nuria Viñolas; Mariano Provencio; Margarita Majem; Angel Artal; Isabel Bover; Pilar Lianes; Ramón DE Las Peñas; Silvia Catot; Javier DE Castro; Ana Blasco; Josefa Terrasa; José Luis Gonzalez-Larriba; Oscar Juan; Manuel Dómine; Reyes Bernabe; Pilar Garrido
Journal:  Anticancer Res       Date:  2016-12       Impact factor: 2.480

9.  Screening for epidermal growth factor receptor mutations in lung cancer.

Authors:  Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

10.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2013-04-04       Impact factor: 5.568

View more
  2 in total

1.  Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report.

Authors:  Annapaola Mariniello; Eleonora Ghisoni; Luisella Righi; Annamaria Catino; Rita Chiari; Alessandro Del Conte; Fausto Barbieri; Fabiana Cecere; Alain Gelibter; Matteo Giajlevra; Hector Soto Parra; Clizia Zichi; Massimo DI Maio; Giorgio Valabrega; Silvia Novello
Journal:  In Vivo       Date:  2019 Nov-Dec       Impact factor: 2.155

2.  Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.

Authors:  Kristof Cuppens; Liesbet Lodewyckx; Ingel Demedts; Lore Decoster; Benoît Colinet; Koen Deschepper; Annelies Janssens; Daniella Galdermans; Thierry Pieters
Journal:  Drugs Real World Outcomes       Date:  2021-03-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.